63 MET immunoreactivity and poor prognosis Acknowledgements We thank Prof. dr. Els Berns, Prof. dr. Vincent Smit and Dr. Marjan van den Brink for their guidance and critical feedback. Conflict of interest No potential conflicts of interest were disclosed. Grant support This study was supported by Innovative Medicines Initiative Joint Undertaking (PREDECT, grant 115188) and the Dutch Cancer Society (KWF; grant EMCR 2011-5006). 3
RkJQdWJsaXNoZXIy MTk4NDMw